Kantify at IFB Industry Seminar on AI in Pharma

Kantify will participate in the upcoming IFB seminar How is AI Transforming Pharma & MedTech?, taking place on 22–23 September 2026 at Waerboom, Groot Bijgaarden.

The two-day programme, organised by the Institute for Biopharma (IFB), brings together academic researchers, clinicians, and industry practitioners to assess where artificial intelligence can create verifiable value across drug development, patient care, and health system operations. Segolene Martin, representing Kantify, will present on Discovering tomorrow's drugs with Artificial Intelligence on the opening day.

The session will describe what Kantify's platform, Sapian, does today: predicting interactions with target proteins, and prioritising compounds for synthesis based on multiple parameters including predicted ADMET properties, and many others.

The seminar is structured around two complementary perspectives. Day one addresses clinical data and the infrastructure that supports it - from voice-to-clinical-data transcription to cross-border trial matching. Day two focuses on decision support in clinical practice, including early detection tools and conversational AI for patient adherence.

Other confirmed speakers include:

• Prof. Lieven Annemans (UGent), who will present findings from a year-long study on AI's impact on health systems and provide a SWOC (Strengths, Weaknesses, Opportunities, Challenges) framework for evaluating AI applications in the sector.

• Prof. Tom Braekeleer (UGent / NEXXTT.HEALTH), offering a practice-oriented introduction to AI and a framework for assessing whether an application meets criteria for what he terms "Acceptable AI."

• Dr. Allison Gilbert (UMons), examining which AI models are already in use by physicians and what that means for how pharmaceutical and device companies should structure their interactions with clinicians.

• Dr. Marc Helbert and Frederik Deman (ZAS), presenting on integrated patient records, clinical decision support, and how hospitals are preparing infrastructure to accommodate AI tools. The event also includes hands-on workshops on assessing where AI can generate value in functions including market access, health technology assessment, and evidence generation. Topics such as automated HTA dossier synthesis, risk-sharing simulators for managed entry agreements, and dynamic KOL profiling will be addressed - not as aspirational concepts, but as tools currently in limited deployment.

The full programme and speaker list are available at ifbseminars.be.